Study Demonstrates Martek's Life'sDHA(TM) Lowers Diastolic Blood Pressure

Main Category: Hypertension
Also Included In: Blood / Hematology;  Nutrition / Diet;  Clinical Trials / Drug Trials
Article Date: 23 Mar 2007 - 0:00 PDT

email to a friend   printer friendly   opinions  

Martek's life'sDHA(TM) from microalgae successfully reduces diastolic blood pressure in middle-aged subjects, according to an independent study published in the April issue of the Journal of Nutrition. The study, conducted at King's College, London, reported a significant reduction in diastolic blood pressure. The investigators noted that this reduction is likely to be of clinical significance with regard to risk of future vascular events. This is the first study to assess the effects on blood pressure of intakes of DHA alone at less than 1.0 g per day. The study was neither funded nor sponsored by Martek Biosciences, but used Martek's life'sDHA(TM) as its algal DHA source.

The study involved 38 middle-aged subjects with an average age of 49 and an average blood pressure of 122/79 mmHg. Subjects randomly received either a 0.7 g per day of DHA or placebo for three months. Diastolic blood pressure decreased by an average of 3.3 mmHg. No significant changes occurred in systolic blood pressure. The daily DHA supplement increased DHA levels in red blood cells (erythrocytes) by 58 percent.

"This research is further evidence supporting the cardiovascular health benefits of Martek's life'sDHA(TM)," said Steve Dubin, CEO of Martek Biosciences.

Martek's life'sDHA(TM) is a vegetarian form of DHA omega-3, a long chain omega-3 fatty acid that serves as a primary building block for the brain and the eye and supports brain, eye and cardiovascular health throughout life. There is a large and growing body of scientific evidence demonstrating that people of all ages, from infants to aging adults, benefit from an adequate supply of DHA omega-3 in the diet. Scientific reviews have noted the importance of DHA omega-3 in proper brain and eye development and function, and there are clinical studies underway to evaluate its role in decreasing the prevalence of certain neurological disorders. Yet despite its importance, Americans have among the lowest dietary intakes of DHA omega-3 in the world.

Martek's life'sDHA(TM) is unique in the market because it is derived from a sustainable and vegetarian source. Made from microalgae under tightly controlled manufacturing conditions, life'sDHA(TM) is free of oceanic contaminants that may be present in certain fish or fish oils. Microalgae are the only vegetarian source of DHA omega-3, the key omega-3 for brain and eye development and function.

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The Company produces life'sDHA(TM), a sustainable and vegetarian source of DHA omega-3, for use in foods, beverages, infant formula, and supplements, and ARA (arachidonic acid), an omega-6 fatty acid, for use in infant formula. For more information on Martek Biosciences, visit http://www.martek.com/.

Sections of this release contain forward-looking statements concerning, among other things, the results of a scientific study involving DHA published in the Journal of Nutrition, the health benefits of life'sDHA(TM), and the science surrounding DHA. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's Form 10-K for the fiscal year ended October 31, 2006 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

Martek Biosciences Corporation
http://www.martekbio.com

• Additional
• References
• Citations